Pancreatic Cancer Research

ResearcherUniversity of PittsburghNo recent work listed

Susannah G. Ellsworth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8546-3642; OpenAlex author ID A5023651604. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2013: 4 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper

Papers 11

  1. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. Last author DOI 10.1001/jamaoncol.2022.6135↗
  2. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  3. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  4. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  5. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  6. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2015.11.026↗
  7. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0b013e3182940ff9↗
  8. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relat… Co-author DOI 10.1007/s13566-013-0115-6↗
  9. Pain management and palliative care in pancreatic cancer. Last author DOI 10.1016/j.currproblcancer.2013.10.003↗
  10. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  11. Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design. Co-author DOI 10.1016/j.ijrobp.2013.09.005↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 4 shared papers, 2021–2022 · strength 0.43
  2. Alessandro Paniccia · 4 shared papers, 2021–2022 · strength 0.43
  3. Aaron J. Grossberg · 1 shared paper, 2023 · strength 0.31
  4. Krishan R. Jethwa · 1 shared paper, 2023 · strength 0.31
  5. Melissa Ellen Hogg · 3 shared papers, 2021–2022 · strength 0.30
  6. Herbert J. Zeh · 3 shared papers, 2021–2022 · strength 0.30
  7. Nathan Bahary · 3 shared papers, 2021–2022 · strength 0.30
  8. Aatur Dilip Singhi · 3 shared papers, 2021–2022 · strength 0.30
  9. Brian A. Boone · 2 shared papers, 2021–2022 · strength 0.21
  10. Adam C. Olson · 2 shared papers, 2021 · strength 0.20
  11. David L. Bartlett · 2 shared papers, 2021 · strength 0.20
  12. Rohit Kumar Das · 2 shared papers, 2021–2022 · strength 0.20
  13. Asif Khalid · 2 shared papers, 2021–2022 · strength 0.20
  14. Joseph M. Herman · 5 shared papers, 2013–2016 · strength 0.18
  15. Daniel A. Laheru · 5 shared papers, 2013–2016 · strength 0.18
  16. Aaron Tyler Wild · 4 shared papers, 2013–2016 · strength 0.14
  17. Matthew H. G. Katz · 1 shared paper, 2022 · strength 0.13
  18. Deesje Doppenberg · 1 shared paper, 2022 · strength 0.13
  19. Marsha Reyngold · 1 shared paper, 2022 · strength 0.13
  20. Jacob L. van Dam · 1 shared paper, 2022 · strength 0.13
  21. Eileen Mary O'Reilly · 1 shared paper, 2022 · strength 0.13
  22. Quisette P. Janssen · 1 shared paper, 2022 · strength 0.13
  23. Laura R. Prakash · 1 shared paper, 2022 · strength 0.13
  24. Bas Groot Koerkamp · 1 shared paper, 2022 · strength 0.13
  25. Marc G. Besselink · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.